NASDAQ · Healthcare · Biotechnology
Cytokinetics, Incorporated
CYTK
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. CEO Robert I. Blum · Market cap $9.6B.
$76.84
-0.34 · -0.44%
52w hi $88.3152w lo $35.22
51
ROUTINE
Current InsiderScore
Corp · 90d
3
0 buys · 3 sales
Cong · 90d
1
1 buys · 0 sales
Signals ≥ 60 · 12mo
0
0 strong · 0 notable
Analyst consensus
—
—
Section 01
Recent Form 4 filings
10 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Jul 30 | Andrew Callos | EVP, Chief Commercial Officer | Sell | 14,000 | $79.88 | −$1.12M | 30 |
| Jul 01 | Andrew Callos | EVP, Chief Commercial Officer | Sell | 15,000 | $85.80 | −$1.29M | 30 |
| Jun 24 | Sung Lee | EVP, Chief Financial Officer | Sell | 38,730 | $82.30 | −$3.19M | 38 |
| May 05 | John T Henderson | Sell | 20,000 | $75.97 | −$1.52M | 28 | |
| May 05 | Sung Lee | EVP, Chief Financial Officer | Sell | 23,906 | $76.87 | −$1.84M | 38 |
| May 01 | Andrew Callos | EVP, Chief Commercial Officer | Sell | 15,857 | $65.00 | −$1.03M | 30 |
| Mar 17 | Robert I Blum | President & CEO | Sell | 23,928 | $62.15 | −$1.49M | 34 |
| Dec 22 | Wendell Wierenga | Sell | 20,000 | $66.14 | −$1.32M | 32 | |
| Dec 05 | Andrew Callos | EVP, Chief Commercial Officer | Sell | 52,486 | $65.95 | −$3.46M | 37 |
| Dec 01 | Edward M. Kaye MD | Sell | 28,064 | $66.72 | −$1.87M | 35 |
Section 02
Recent STOCK Act disclosures
1 disclosures on file
| Disclosed | Legislator | Chamber · State | Action | Range | Midpoint | Delay | Score |
|---|---|---|---|---|---|---|---|
| Jul 03 | Gilbert Cisneros | House · CA | Buy | $1,001 - $15,000 | $8K | 3 d | 51 |
Section 03
InsiderScore history
Rolling 12 months · peak score per month
SepOctNovDecJanFebMarAprMayJunJulAug